Prooxidant-Antioxidant Balance of The Brain of Rats with Cerebral Ischemia with The Introduction Of L-Name, L-Arginine, And Omega-3 Polyunsaturated Fatty Acids

The search for new approaches to the treatment of acute ischemic stroke is one of the urgent problems of experimental and clinical neurology. This is due to the fact that cerebrovascular diseases of ischemic origin tend to grow, rejuvenate, are associated with a severe clinical course, high rates of disability and mortality. One of the promising neuroprotective amino acids is L-arginine. Most of the effects caused by this amino acid are associated with its ability to increase the formation of NO, acting as a source for its formation. An important role of ω-3 polyunsaturated fatty acids (Omega-3 PUFAs) is to ensure the functioning of cell membranes, transmembrane ion channels and the regulation of physiological processes through the synthesis of lipid mediators, which, lining up in the phospholipid layer of cell membranes, affect their fluidity. Cerebral ischemia is characterized by the activation of prooxidant mechanisms, as well as the inhibition of energy metabolism in the brain tissue. The introduction of the drug «Omega-3 PUFA» has a corrective effect on the indicators of oxidative stress in SCI. The use of «Omega-3 PUFA» in animals of the group with cerebral ischemia and the introduction of a non-selective NOS inhibitor – L-NAME did not have a positive effect.